MC-Val-Cit-PAB-MMAE - CAS 646502-53-6

MC-Val-Cit-PAB-MMAE - CAS 646502-53-6 Catalog number: BADC-00029

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

MC-Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate.

General Information

Category
ADCs Cytotoxin
Product Name
MC-Val-Cit-PAB-MMAE
CAS
646502-53-6
Catalog Number
BADC-00029
Molecular Formula
C68H105N11O15
Molecular Weight
1316.63

Chemical Structure

  • MC-Val-Cit-PAB-MMAE

Ordering Information

Catalog Number Size Price Stock Quantity
BADC-00029 1 mg $149 In stock
Add to cart
Purity
>98%
Synonyms
VcMMAE; Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E; Vedotin
Shipping
Room temperature, or blue ice upon request.
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN4C(=O)C=CC4=O
InChI Key
NLMBVBUNULOTNS-HOKPPMCLSA-N
InChI
InChI=1S/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1
Sequence
VXXVV
1.Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific.
Gikanga B1, Adeniji NS1, Patapoff TW1, Chih HW1, Yi L1. Bioconjug Chem. 2016 Apr 20;27(4):1040-9. doi: 10.1021/acs.bioconjchem.6b00055. Epub 2016 Mar 10.
Antibody-drug conjugates (ADCs) require thorough characterization and understanding of product quality attributes. The framework of many ADCs comprises one molecule of antibody that is usually conjugated with multiple drug molecules at various locations. It is unknown whether the drug release rate from the ADC is dependent on drug location, and/or local environment, dictated by the sequence and structure of the antibody carrier. This study addresses these issues with valine-citrulline-monomethylauristatin E (vc-MMAE)-based ADC molecules conjugated at reduced disulfide bonds, by evaluating the cathepsin B catalyzed drug release rate of ADC molecules with different drug distributions or antibody carriers. MMAE drug release rates at different locations on ADC I were compared to evaluate the impact of drug location. No difference in rates was observed for drug released from the VH, VL, or CH2 domains of ADC I. Furthermore, four vc-MMAE ADC molecules were chosen as substrates for cathepsin B for evaluation of Michaelis-Menten parameters.

View All ADCs Cytotoxin Sort Specific Products

View All ADCs Cytotoxin with Linkers Sort Specific Products

View All ADCs Linker Sort Specific Products

Related Products

Get in Touch

Verification code
Historical Records: NH2-PEG2-C2-Boc | Propargyl-PEG1-SS-PEG1-PFP ester | 3-Azidopropionic Acid Sulfo-NHS ester | 4-Formyl-N-(2-(p-Tolyloxy)ethyl)benzamide | BMPS | Thapsigargin | 4-Formyl-N-(2-(o-Tolyloxy)ethyl)benzamide | Fmoc-Gly-Gly-Phe-OH | β-Estradiol-6-CMO-PEG3-biotin | LTx-004 | MC-Val-Cit-PAB-MMAE
Inquiry Basket